Shares of Compugen (CGEN) move up 6.9% in premarket trading after the firm announces that its CGEN-15001T cancer drug demonstrates "significant potential" for cancer immunotherapy. The firm says it ran studies using an antibody specifically recognizing CGEN-15001T.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs